Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Management of augmentation of restless legs syndrome with rotigotine: a 1-year observational study.

Trenkwalder C, Canelo M, Lang M, Schroeder H, Kelling D, Berkels R, Schollmayer E, Heidbrede T, Benes H.

Sleep Med. 2017 Feb;30:257-265. doi: 10.1016/j.sleep.2015.10.006. Epub 2015 Nov 11.

PMID:
26896370
2.

Caregivers' and physicians' attitudes to rotigotine transdermal patch versus oral Parkinson's disease medication: an observational study.

Sieb JP, Themann P, Warnecke T, Lauterbach T, Berkels R, Grieger F, Lorenzl S.

Curr Med Res Opin. 2015 May;31(5):967-74. doi: 10.1185/03007995.2015.1030376.

PMID:
25772231
3.

Reduction of gastrointestinal symptoms in Parkinson's disease after a switch from oral therapy to rotigotine transdermal patch: a non-interventional prospective multicenter trial.

Woitalla D, Kassubek J, Timmermann L, Lauterbach T, Berkels R, Grieger F, Müller T.

Parkinsonism Relat Disord. 2015 Mar;21(3):199-204. doi: 10.1016/j.parkreldis.2014.11.024. Epub 2014 Dec 4.

PMID:
25595315
4.

New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo.

Valhondo M, Marco I, Martín-Fontecha M, Vázquez-Villa H, Ramos JA, Berkels R, Lauterbach T, Benhamú B, López-Rodríguez ML.

J Med Chem. 2013 Oct 24;56(20):7851-61. doi: 10.1021/jm400766k. Epub 2013 Oct 8.

PMID:
24050112
5.

Effectiveness and tolerability of rotigotine transdermal patch for the treatment of restless legs syndrome in a routine clinical practice setting in Germany.

Stiasny-Kolster K, Berg D, Hofmann WE, Berkels R, Grieger F, Lauterbach T, Schollmayer E, Bachmann CG.

Sleep Med. 2013 Jun;14(6):475-81. doi: 10.1016/j.sleep.2013.02.013. Epub 2013 May 11.

PMID:
23668924
6.

Preconditioning by toll-like receptor 2 agonist Pam3CSK4 reduces CXCL1-dependent leukocyte recruitment in murine myocardial ischemia/reperfusion injury.

Mersmann J, Berkels R, Zacharowski P, Tran N, Koch A, Iekushi K, Dimmeler S, Granja TF, Boehm O, Claycomb WC, Zacharowski K.

Crit Care Med. 2010 Mar;38(3):903-9. doi: 10.1097/CCM.0b013e3181ce50e6. Erratum in: Crit Care Med. 2010 Jun;38(6):1509.

PMID:
20081527
7.

The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease.

Scheller D, Ullmer C, Berkels R, Gwarek M, Lübbert H.

Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):73-86. doi: 10.1007/s00210-008-0341-4. Epub 2008 Aug 14.

PMID:
18704368
8.

Inducible nitric oxide synthase and heme oxygenase-1 in the lung during lipopolysaccharide tolerance and cross tolerance.

Koch A, Boehm O, Zacharowski PA, Loer SA, Weimann J, Rensing H, Foster SJ, Schmidt R, Berkels R, Reingruber S, Zacharowski K.

Crit Care Med. 2007 Dec;35(12):2775-84.

PMID:
17901834
9.

Toll-like receptor 9 expression in murine and human adrenal glands and possible implications during inflammation.

Tran N, Koch A, Berkels R, Boehm O, Zacharowski PA, Baumgarten G, Knuefermann P, Schott M, Kanczkowski W, Bornstein SR, Lightman SL, Zacharowski K.

J Clin Endocrinol Metab. 2007 Jul;92(7):2773-83. Epub 2007 May 1.

PMID:
17473064
10.

Toll-like receptor 4 plays a crucial role in the immune-adrenal response to systemic inflammatory response syndrome.

Zacharowski K, Zacharowski PA, Koch A, Baban A, Tran N, Berkels R, Papewalis C, Schulze-Osthoff K, Knuefermann P, Zähringer U, Schumann RR, Rettori V, McCann SM, Bornstein SR.

Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6392-7. Epub 2006 Apr 10.

11.

Endothelial antioxidant actions of dihydropyridines and angiotensin converting enzyme inhibitors.

Rosenkranz AC, Lob H, Breitenbach T, Berkels R, Roesen R.

Eur J Pharmacol. 2006 Jan 4;529(1-3):55-62. Epub 2005 Nov 28.

PMID:
16313901
12.

Antioxidant and nitric oxide-sparing actions of dihydropyridines and ACE inhibitors differ in human endothelial cells.

Lob H, Rosenkranz AC, Breitenbach T, Berkels R, Drummond G, Roesen R.

Pharmacology. 2006;76(1):8-18. Epub 2005 Oct 10.

PMID:
16220025
13.

Different antioxidative potencies of dihydropyridine calcium channel modulators in various models.

Berkels R, Breitenbach T, Bartels H, Taubert D, Rosenkranz A, Klaus W, Roesen R.

Vascul Pharmacol. 2005 Mar;42(4):145-52. Epub 2005 Jan 22.

PMID:
15820440
14.

Discovery of the ergothioneine transporter.

Gründemann D, Harlfinger S, Golz S, Geerts A, Lazar A, Berkels R, Jung N, Rubbert A, Schömig E.

Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5256-61. Epub 2005 Mar 28.

15.

Acute effects of glucose and insulin on vascular endothelium.

Taubert D, Rosenkranz A, Berkels R, Roesen R, Schömig E.

Diabetologia. 2004 Dec;47(12):2059-71. Epub 2004 Dec 15.

PMID:
15662548
16.

Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action.

Taubert D, Berkels R, Grosser N, Schröder H, Gründemann D, Schömig E.

Br J Pharmacol. 2004 Sep;143(1):159-65. Epub 2004 Aug 2.

17.

Measurement of nitric oxide by reconversion of nitrate/nitrite to NO.

Berkels R, Purol-Schnabel S, Roesen R.

Methods Mol Biol. 2004;279:1-8.

PMID:
15199232
18.

Influence of processing parameters on acrylamide formation during frying of potatoes.

Taubert D, Harlfinger S, Henkes L, Berkels R, Schömig E.

J Agric Food Chem. 2004 May 5;52(9):2735-9.

PMID:
15113184
19.

Agmatine signaling: odds and threads.

Berkels R, Taubert D, Gründemann D, Schömig E.

Cardiovasc Drug Rev. 2004 Spring;22(1):7-16. Review.

PMID:
14978515
20.

[Aspirin--a suitable drug for cancer prevention?].

Taubert D, Berkels R, Schömig E.

Dtsch Med Wochenschr. 2004 Feb 27;129(9):439-42. Review. German. No abstract available.

PMID:
14970916
21.

The localisation of the extraneuronal monoamine transporter (EMT) in rat brain.

Haag C, Berkels R, Gründemann D, Lazar A, Taubert D, Schömig E.

J Neurochem. 2004 Jan;88(2):291-7.

22.

Reaction rate constants of superoxide scavenging by plant antioxidants.

Taubert D, Breitenbach T, Lazar A, Censarek P, Harlfinger S, Berkels R, Klaus W, Roesen R.

Free Radic Biol Med. 2003 Dec 15;35(12):1599-607.

PMID:
14680683
23.

Amlodipine increases endothelial nitric oxide by dual mechanisms.

Berkels R, Taubert D, Bartels H, Breitenbach T, Klaus W, Roesen R.

Pharmacology. 2004 Jan;70(1):39-45.

PMID:
14646355
24.

Vascular protective effects of dihydropyridine calcium antagonists. Involvement of endothelial nitric oxide.

Berkels R, Taubert D, Rosenkranz A, Rösen R.

Pharmacology. 2003 Dec;69(4):171-6. Review.

PMID:
14624055
25.

The HMG-CoA reductase inhibitor cerivastatin enhances the nitric oxide bioavailability of the endothelium.

Berkels R, Nouri SK, Taubert D, Bartels H, Roesen P, Roesen R, Klaus W.

J Cardiovasc Pharmacol. 2003 Sep;42(3):356-63.

PMID:
12960680
26.

Chocolate and blood pressure in elderly individuals with isolated systolic hypertension.

Taubert D, Berkels R, Roesen R, Klaus W.

JAMA. 2003 Aug 27;290(8):1029-30. No abstract available.

PMID:
12941673
27.

Genetic variability of the extraneuronal monoamine transporter EMT (SLC22A3).

Lazar A, Gründemann D, Berkels R, Taubert D, Zimmermann T, Schömig E.

J Hum Genet. 2003;48(5):226-30. Epub 2003 Apr 9.

PMID:
12768439
28.

Upregulation and activation of eNOS by resveratrol.

Taubert D, Berkels R.

Circulation. 2003 Mar 25;107(11):e78-9; author reply e78-9. No abstract available.

PMID:
12654625
29.

Detection of a novel 1905C-->T mutation within the dihydropyrimidine dehydrogenase gene and potential for misclassification with the exon 14-skipping mutation.

Lazar A, Jan Weissenborn S, Gründemann D, Berkels R, Fuhr U, Pfister H, Schömig E.

Clin Chem. 2003 Apr;49(4):707-8. No abstract available.

30.
31.

Nitric oxide formation and corresponding relaxation of porcine coronary arteries induced by plant phenols: essential structural features.

Taubert D, Berkels R, Klaus W, Roesen R.

J Cardiovasc Pharmacol. 2002 Nov;40(5):701-13.

PMID:
12409979
32.

Nisoldipine increases the bioavailability of endothelial NO.

Berkels R, Roesen R, Bartels H, Purol-Schnabel S, Kirmiziguel I, Farmer H, Born GV, Klaus W.

Naunyn Schmiedebergs Arch Pharmacol. 2001 Aug;364(2):110-6.

PMID:
11534850
33.

The selective guanylate cyclase inhibitor ODQ reduces multiple organ injury in rodent models of Gram-positive and Gram-negative shock.

Zacharowski K, Berkels R, Olbrich A, Chatterjee PK, Cuzzocrea S, Foster SJ, Thiemermann C.

Crit Care Med. 2001 Aug;29(8):1599-608.

PMID:
11505136
34.

Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil.

Berkels R, Klotz T, Sticht G, Englemann U, Klaus W.

J Cardiovasc Pharmacol. 2001 Apr;37(4):413-21.

PMID:
11300654
35.

Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms.

Berkels R, Egink G, Marsen TA, Bartels H, Roesen R, Klaus W.

Hypertension. 2001 Feb;37(2):240-5.

PMID:
11230278
36.

A new method to measure nitrate/nitrite with a NO-sensitive electrode.

Berkels R, Purol-Schnabel S, Roesen R.

J Appl Physiol (1985). 2001 Jan;90(1):317-20.

37.

The calcium antagonist nifedipine inhibits the uptake of acetylated LDL into endothelial cells.

Berkels R, Hass U, Klaus W.

Naunyn Schmiedebergs Arch Pharmacol. 2000 Aug;362(2):91-5.

PMID:
10961369
38.

Simultaneous measurement of intracellular Ca(2+) and nitric oxide: a new method.

Berkels R, Dachs C, Roesen R, Klaus W.

Cell Calcium. 2000 May;27(5):281-6.

PMID:
10859594
39.

[Calcium antagonists more closely examined. A known drug group with novel working principles?].

Berkels R, Klaus W.

Dtsch Med Wochenschr. 2000 Apr 28;125(17):531-3. Review. German. No abstract available.

PMID:
10829798
40.

Nifedipine and Bay K 8644 Induce an increase of

Berkels R, Mueller A, Roesen R, Klaus W.

J Cardiovasc Pharmacol Ther. 1999 Jul;4(3):175-181.

PMID:
10684539
41.

Nitric oxide causes a cGMP-independent intracellular calcium rise in porcine endothelial cells-a paradox?

Berkels R, Suerhoff S, Roesen R, Klaus W.

Microvasc Res. 2000 Jan;59(1):38-44.

PMID:
10625569
42.

Dual mode of action of dihydropyridine calcium antagonists: a role for nitric oxide.

Dhein S, Salameh A, Berkels R, Klaus W.

Drugs. 1999 Sep;58(3):397-404. Review.

PMID:
10493269
43.

Switched single-electrode voltage-clamp amplifiers allow precise measurement of gap junction conductance.

Müller A, Lauven M, Berkels R, Dhein S, Polder HR, Klaus W.

Am J Physiol. 1999 Apr;276(4):C980-7. doi: 10.1152/ajpcell.1999.276.4.C980.

PMID:
10199830
44.

Current status of platelet NO synthases.

Berkels R, Stockklauser K, Rösen P, Rösen R.

Thromb Res. 1997 Jul 1;87(1):51-5. Review. No abstract available.

PMID:
9253799
45.

Controlled release of antibiotics from biomedical polyurethanes: morphological and structural features.

Schierholz JM, Steinhauser H, Rump AF, Berkels R, Pulverer G.

Biomaterials. 1997 Jun;18(12):839-44.

PMID:
9184747
46.

Evidence for a NO synthase in porcine platelets which is stimulated during activation/aggregation.

Berkels R, Bertsch A, Zuther T, Dhein S, Stockklauser K, Rösen P, Rösen R.

Eur J Haematol. 1997 May;58(5):307-13.

PMID:
9222285
47.

The calcium modulator nifedipine exerts its antiaggregatory property via a nitric oxide mediated process.

Berkels R, Klaus W, Boller M, Rösen R.

Thromb Haemost. 1994 Aug;72(2):309-12.

PMID:
7831670
48.

Supplemental Content

Loading ...
Support Center